| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PROT.23085 |
| P698 | PubMed publication ID | 21732420 |
| P50 | author | Peter M. Tessier | Q41845651 |
| P2093 | author name string | Moumita Bhattacharya | |
| Joseph M Perchiacca | |||
| P2860 | cites work | DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis | Q24529935 |
| The 3D profile method for identifying fibril-forming segments of proteins | Q24545011 | ||
| Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface | Q27639286 | ||
| Exploring the Capacity of Minimalist Protein Interfaces: Interface Energetics and Affinity Maturation to Picomolar KD of a Single-domain Antibody with a Flat Paratope | Q27648417 | ||
| Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains | Q27649162 | ||
| General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold | Q27652903 | ||
| The crystal structure of a llama heavy chain variable domain | Q27733333 | ||
| Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme | Q27733338 | ||
| Protein production by auto-induction in high density shaking cultures | Q27860514 | ||
| Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies | Q28141943 | ||
| Domain antibodies: proteins for therapy | Q28211838 | ||
| Naturally occurring antibodies devoid of light chains | Q28269589 | ||
| A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. | Q30342690 | ||
| Contributions of CDR3 to V H H domain stability and the design of monobody scaffolds for naive antibody libraries | Q30788281 | ||
| Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. | Q52525981 | ||
| 1H, 13C and 15N assignments of a camelid nanobody directed against human α-synuclein | Q56620174 | ||
| Antigen Binding and Solubility Effects upon the Veneering of a Camel VHH in Framework-2 to Mimic a VH | Q57838453 | ||
| Biophysical Properties of Camelid VHHDomains Compared to Those of Human VH3 Domains† | Q57839989 | ||
| Different Equilibrium Stability Behavior of ScFv Fragments: Identification, Classification, and Improvement by Protein Engineering† | Q57840032 | ||
| Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama | Q30879327 | ||
| Phage display in pharmaceutical biotechnology | Q30974739 | ||
| Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties | Q31055387 | ||
| Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries | Q31079441 | ||
| A new approach for rapidly reshaping single-chain antibody in vitro by combining DNA shuffling with ribosome display | Q31097923 | ||
| Biophysical properties of human antibody variable domains | Q31122335 | ||
| Antibody affinity maturation using bacterial surface display. | Q31985056 | ||
| Antibody VH domains as small recognition units | Q32060510 | ||
| The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops | Q33191252 | ||
| Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach | Q33257515 | ||
| AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides | Q33275645 | ||
| Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils | Q33307478 | ||
| Sequence determinants of protein aggregation in human VH domains | Q33380007 | ||
| Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points | Q33387145 | ||
| Identifying the amylome, proteins capable of forming amyloid-like fibrils | Q33734407 | ||
| Single domain antibodies: comparison of camel VH and camelised human VH domains | Q33825185 | ||
| Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains | Q34214306 | ||
| Making antibodies by phage display technology | Q34328794 | ||
| Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains | Q34662422 | ||
| Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli | Q35896400 | ||
| Applications of ribosome display to antibody drug discovery | Q36040839 | ||
| Single-domain antibody fragments with high conformational stability | Q36639059 | ||
| Engineered turns of a recombinant antibody improve its in vivo folding | Q36706337 | ||
| Yeast surface display for screening combinatorial polypeptide libraries | Q36865126 | ||
| Formulation and manufacturability of biologics | Q37625509 | ||
| Supercharging proteins can impart unusual resilience | Q39273315 | ||
| Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire | Q40387210 | ||
| PCR mediated gene synthesis. | Q40450334 | ||
| Structural repertoire of the human VH segments | Q42603998 | ||
| Exploring the sequence determinants of amyloid structure using position-specific scoring matrices | Q44106880 | ||
| Conserved amino acid networks involved in antibody variable domain interactions | Q44236368 | ||
| Thermodynamically stable aggregation-resistant antibody domains through directed evolution | Q44842924 | ||
| The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains | Q46167685 | ||
| Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold | Q47919372 | ||
| Engineering antibody affinity by yeast surface display. | Q51636979 | ||
| The PASTA server for protein aggregation prediction. | Q51907234 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| mutational analysis | Q1955810 | ||
| P304 | page(s) | 2637-2647 | |
| P577 | publication date | 2011-07-05 | |
| P1433 | published in | Proteins | Q7251514 |
| P1476 | title | Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions | |
| P478 | volume | 79 |
| Q35014937 | A novel heavy domain antibody library with functionally optimized complementarity determining regions |
| Q28817608 | Advances in Antibody Design |
| Q90312467 | Antibody Aggregation: Insights from Sequence and Structure |
| Q36254449 | Computer-aided antibody design |
| Q36548388 | Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide |
| Q42143637 | Determinants of the assembly and function of antibody variable domains |
| Q51722272 | Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. |
| Q37724050 | Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability |
| Q36140177 | Engineered Autonomous Human Variable Domains |
| Q37961564 | Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins |
| Q35044156 | Engineered antibody variable and constant domains as therapeutic candidates |
| Q34527769 | Frontier of therapeutic antibody discovery: The challenges and how to face them |
| Q30372369 | Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies |
| Q37388808 | Functional consequences of complementarity-determining region deactivation in a multifunctional anti-nucleic acid antibody. |
| Q27670560 | General strategy for the generation of human antibody variable domains with increased aggregation resistance |
| Q90723419 | Generation of a Nebulizable CDR-Modified MERS-CoV Neutralizing Human Antibody |
| Q92216145 | Germinality does not necessarily define mAb expression and thermal stability |
| Q30462680 | High-throughput analysis of concentration-dependent antibody self-association. |
| Q61453152 | Identification of B cell epitopes enhanced by protein unfolding and aggregation |
| Q27002558 | Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions |
| Q42210192 | Improving the biophysical properties of anti-ricin single-domain antibodies |
| Q35748485 | Increased Fab thermoresistance via VH-targeted directed evolution |
| Q104064463 | Local environment effects on charged mutations for developing aggregation-resistant monoclonal antibodies |
| Q37451005 | Lysine and arginine content of proteins: computational analysis suggests a new tool for solubility design. |
| Q91408599 | Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs |
| Q57839816 | Modification of the kinetic stability of immunoglobulin G by solvent additives |
| Q41382042 | Molecular dynamics simulations and docking enable to explore the biophysical factors controlling the yields of engineered nanobodies |
| Q38017581 | Molecular engineering of antibodies for therapeutic and diagnostic purposes |
| Q36168796 | Nanoyeast and Other Cell Envelope Compositions for Protein Studies and Biosensor Applications. |
| Q91637594 | Net charge of antibody complementarity-determining regions is a key predictor of specificity |
| Q34347071 | Next generation phage display by use of pVII and pIX as display scaffolds |
| Q53642992 | Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. |
| Q90212119 | Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics |
| Q49550316 | Peptides as Potential Therapeutics for Alzheimer's Disease |
| Q42367802 | Sequence composition predicts immunoglobulin superfamily members that could share the intrinsically disordered properties of antibody CH1 domains |
| Q26859495 | Stability engineering of the human antibody repertoire |
| Q35018813 | Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments |
| Q30384777 | Structural hot spots for the solubility of globular proteins. |
| Q27676164 | Structure of a low-melting-temperature anti-cholera toxin: llama VHH domain |
| Q34097620 | Therapeutic protein aggregation: mechanisms, design, and control |
| Q89841446 | Using protein engineering to understand and modulate aggregation |
Search more.